Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
about
Cancer Immunotherapies: Are They as Effective in the Elderly?Avelumab: First Global Approval.PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.Avelumab demonstrates promise in advanced NSCLC.Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?Drug Monographs: Avelumab and Ribociclib.Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Trial watch: Immune checkpoint blockers for cancer therapy.PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.PD-1/PD-L1 Axis in Lung Cancer.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.Update on Immunohistochemistry for the Diagnosis of Lung Cancer.PD-L1 inhibitors in the pipeline: Promise and progress.Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.Lung cancer, elderly and immune checkpoint inhibitors.Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?The emerging treatment landscape of advanced non-small cell lung cancer.Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).New advances in immunotherapy for non-small cell lung cancerBiomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
P2860
Q38679662-9553D001-5216-4402-8D7A-1133CF1A39CAQ39272798-403E3BB3-8C69-46F1-A65C-4D3474BFDA76Q42371630-3C9DAF2C-1EDD-4BBD-B988-D271BE1E87E0Q42688279-AB9065C5-4817-47DE-B350-7657FDF16EBBQ46046777-C02AE80D-4C4E-4085-85EA-F3D94D18D19EQ46132734-D9A0BE9B-B52D-47A9-922A-3E9695816F2CQ47111602-E422AC64-34BC-4F30-ADEC-5C8A80868A1EQ47111652-A1E2D145-60EF-453B-9256-D556EE5D861BQ47125773-57B8AA87-20AA-4237-842F-2CC8FB695F5BQ47140225-D20B9A7A-61EE-4C0E-AD04-377A98A141F9Q47148072-F478645A-D888-4282-947F-27302C569731Q47155204-DCA5E57E-3006-4068-BB1F-C2100B71940AQ47157402-E4D3207E-CC12-4E1B-BAC2-15C1D8157067Q47160465-58E1BB12-A6DB-474E-9A1E-8E86A9460B1EQ47185616-03ACBBE1-7D08-42F9-A4A0-E71C5ABCC679Q47277879-D7C84875-0AE5-4154-B974-EE74EFB5D465Q47393365-E7622CC6-F2D8-4B9C-BD82-52546CBF02B5Q47422615-6A0B8B3F-3AA5-4196-B9FF-77974CC75AE9Q47440377-8A206DDD-557B-4C97-8DCA-29C4FEE6F776Q47584566-A341B0B7-18E8-4171-912A-6B3083B4D1C5Q47717168-A968CB34-567D-4392-BA56-EB0543FA4BB4Q47936526-C550EF58-477B-4CE8-A99D-84A40F0448BBQ48141292-FB8A4E68-2D31-4581-A9CD-8CA400A79E79Q50070316-B887D1E3-C233-49EA-809C-EECCC998F58FQ50104904-9BD3E5ED-C790-4C70-BF32-ADAAD19EB23CQ51733982-41D5FF8F-4B7F-42D6-8979-8687BA3C5FABQ52731766-A87BE9F5-CBE1-4138-8821-57D0D0FDB1DFQ53121293-E3F1ACB6-DEB0-4B40-AD8B-D099F6A76CBAQ53358653-AB950409-C95A-410C-8603-8CC50648FD81Q55026862-325E4EBA-1F7F-4C00-A505-78DC89F9C0EFQ55238859-8B7EAC2F-FF0D-40B4-A1D8-905AD0F32070Q55284597-34025C59-5F61-48F4-A817-A0CAD3587161Q55311366-E99C543E-CA99-404C-B414-338C052B427EQ55316781-2DC8A694-281A-4D34-A9EE-7C84B17C635BQ55338007-FBC342E8-F195-4533-BC06-027F26A231FAQ55341383-FC51A76B-463C-4FD7-87B6-319E7D862C36Q55342455-2225F445-70C8-4683-949A-961A2E6AB2F1Q55497366-11CFF4FF-50FC-4C1F-A61C-D8D66D414664Q56890070-DA641243-9821-4D40-AC1E-075AFB28F31EQ56891609-1D0B25CA-5D02-4EF1-B9E5-64CBB19D8623
P2860
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Avelumab for patients with pre ...... e, open-label, phase 1b trial.
@en
type
label
Avelumab for patients with pre ...... e, open-label, phase 1b trial.
@en
prefLabel
Avelumab for patients with pre ...... e, open-label, phase 1b trial.
@en
P2093
P2860
P1433
P1476
Avelumab for patients with pre ...... e, open-label, phase 1b trial.
@en
P2093
Anja von Heydebreck
Arun Rajan
David R Spigel
Deborah J L Wong
Hans Juergen Grote
James L Gulley
Jason Chandler
Jean-Marie Cuillerot
Joseph Leach
P2860
P304
P356
10.1016/S1470-2045(17)30240-1
P50
P577
2017-03-31T00:00:00Z